ImmunoFree — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $2M

Overview

ImmunoFree is a private, clinical-stage biotech targeting a paradigm shift in post-transplant care by using stem cell technology to induce immune tolerance, thereby freeing patients from lifelong immunosuppressive drugs. The company appears to be advancing its programs through clinical trials at major academic medical centers, as evidenced by patient testimonials and press coverage from institutions like Northwestern Medicine. With a prestigious Scientific Advisory Board and a focus on kidney transplantation, ImmunoFree is positioned to address a significant unmet need with potentially transformative clinical and economic benefits.

TransplantationImmunology

Technology Platform

Stem cell-based therapy platform designed to induce immune tolerance in organ transplant recipients, potentially involving donor-derived or engineered hematopoietic or regulatory cells.

Funding History

1

Total raised:$2M

Grant$2MNIH SBIRMar 15, 2023

Opportunities

The primary opportunity is to establish a new standard of care in transplantation, eliminating lifelong immunosuppression and its associated costs and complications.

This addresses a massive unmet need with a high-value, potentially curative one-time therapy, offering significant value to patients, providers, and payers like Medicare.

Risk Factors

Key risks include clinical failure to demonstrate durable tolerance and an acceptable safety profile in larger trials.

Commercialization risks involve the complexity of delivering a cell therapy in transplant centers and securing adequate reimbursement from payers for a high upfront cost, despite long-term savings.

Competitive Landscape

The competitive landscape includes other biotechs and academic consortia exploring cellular therapies (Tregs, stem cells) and drug regimens for tolerance induction. ImmunoFree's key differentiator appears to be its focus on a specific stem cell-based platform and its collaboration with a premier network of transplant centers through its Scientific Advisory Board.

More companies in Cell & Gene Therapy →More companies in United States →